GLP-1 receptor agonists like semaglutide and liraglutide showed no significant impact on skeletal muscle mass when combined with intensive cardiac rehabilitation exercise programs. Among 468 patients, the 67 taking GLP-1 medications for a median 231 days experienced similar muscle preservation compared to non-users, with only a 0.62% difference in muscle mass change that wasn't statistically significant. This finding addresses a critical concern in obesity medicine. While GLP-1 drugs effectively promote weight loss, clinicians have worried about potential muscle wasting, particularly in older adults already at sarcopenia risk. The muscle-preserving effects observed here likely stem from the structured exercise component, which included both cardiovascular and resistance training typical of cardiac rehabilitation programs. However, this study's observational design and specific population—cardiac patients in supervised programs—limits broader generalizability. The real-world question remains whether GLP-1 users without structured exercise face muscle loss risks. This research supports the emerging clinical strategy of pairing GLP-1 therapy with exercise programming, potentially optimizing body composition changes by maximizing fat loss while preserving metabolically active muscle tissue.